<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00562289</url>
  </required_header>
  <id_info>
    <org_study_id>P060406</org_study_id>
    <nct_id>NCT00562289</nct_id>
  </id_info>
  <brief_title>Patent Foramen Ovale Closure or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence</brief_title>
  <acronym>CLOSE</acronym>
  <official_title>Closure of Patent Foramen Ovale or Anticoagulants Versus Antiplatelet Therapy to Prevent Stroke Recurrence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A patent foramen ovale (PFO) is found more frequently in patients with an ischemic stroke&#xD;
      than in control subjects.&#xD;
&#xD;
      Therapeutic options to prevent stroke recurrence include antiplatelet drugs, oral&#xD;
      anticoagulants, and transcatheter closure of the foramen. However, there are no published&#xD;
      studies showing convincingly the superiority of any one of these strategies in preventing&#xD;
      stroke recurrence.&#xD;
&#xD;
      The aim of this randomized clinical trial is to assess whether chronic anticoagulation on the&#xD;
      one hand and transcatheter on the other hand are superior to chronic antiplatelet therapy in&#xD;
      preventing stroke recurrence.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Secondary prevention for stroke patients with PFO is a subject of considerable debate.&#xD;
      Therapeutic options include antiplatelet drugs, oral anticoagulants, and transcatheter&#xD;
      closure of the foramen. There are no published studies showing convincingly the superiority&#xD;
      of any one of these strategies in preventing stroke recurrence. All the therapeutic options&#xD;
      have some risks and unless randomised trials can define who should be treated with what (if&#xD;
      anything), and for how long, we could end up exposing patients to unnecessary complications&#xD;
      of treatment.&#xD;
&#xD;
      The primary objective of this study is to assess whether chronic anticoagulation (INR 2 to 3)&#xD;
      on the one hand and endovascular treatment on the other hand are superior to chronic&#xD;
      antiplatelet therapy in preventing stroke recurrence in young (16 to 60 years) patients with&#xD;
      a PFO (&gt; 30 microbubbles or associated with an atrial septal aneurysm) and an otherwise&#xD;
      unexplained ischaemic stroke.&#xD;
&#xD;
      Secondary objectives of the study are:&#xD;
&#xD;
        -  to evaluate the safety of the three therapeutic options, in terms of major drug-,&#xD;
           device- or procedure-related complications, in order to allow a benefit/risk assessment&#xD;
           of each therapeutic option in this population.&#xD;
&#xD;
        -  to assess the rate of technical success and effectiveness of endovascular procedure to&#xD;
           treat PFO and ASA.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2007</start_date>
  <completion_date type="Actual">December 2016</completion_date>
  <primary_completion_date type="Actual">December 2016</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>stroke(fatal or not)</measure>
    <time_frame>during the follow up (between 2 or 9 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Disabling stroke</measure>
    <time_frame>during the follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke</measure>
    <time_frame>during the follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cerebral haemorrhage</measure>
    <time_frame>during the follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ischemic stroke, TIA, or systemic embolism</measure>
    <time_frame>during the follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death (all causes)</measure>
    <time_frame>during the follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vascular death</measure>
    <time_frame>during the follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Moderate to severe bleeding complications</measure>
    <time_frame>during the follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Procedural or device complications</measure>
    <time_frame>within 30 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">664</enrollment>
  <condition>Ischemic Stroke</condition>
  <condition>Patent Foramen Ovale</condition>
  <condition>Atrial Septal Aneurysm</condition>
  <condition>Migraine</condition>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>aspirin use like antiplatelet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anticoagulant</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Antivitamins K or rivaroxaban or dabigatran or apixaban</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Devices for PFO closure</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Devices for PFO closure</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <description>during the follow up</description>
    <arm_group_label>aspirin</arm_group_label>
    <other_name>clopidogrel</other_name>
    <other_name>combination aspirin-dipyridamole</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antivitamins K or rivaroxaban or dabigatran or apixaban</intervention_name>
    <description>during the follow up</description>
    <arm_group_label>anticoagulant</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Devices for PFO closure</intervention_name>
    <description>endovascular treatment no longer than 21 days after the random.</description>
    <arm_group_label>Devices for PFO closure</arm_group_label>
    <other_name>Each device for PFO closure must have the CE mark</other_name>
    <other_name>and be approved by the Interventional Cardiology Committee</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female, 16 &lt;= age &lt;= 60 ans.&#xD;
&#xD;
          -  Recent (&lt;= 6 months) ischemic stroke documented by CT-san or MRI (whatever the&#xD;
             duration of symptoms: shorter or longer than 24 hours).&#xD;
&#xD;
          -  Modified Rankin score &lt;=3.&#xD;
&#xD;
          -  Absence of any other identifiable cause of stroke&#xD;
&#xD;
          -  Presence of a PFO with at least one of the following characteristics:&#xD;
&#xD;
               -  right-to-left shunt &gt; 30 microbubbles, at rest or during provocative manoeuvres,&#xD;
                  by TTE ou TOE&#xD;
&#xD;
               -  associated ASA (base ≥ à 15 mm, total excursion &gt; à 10 mm) by TOE&#xD;
&#xD;
          -  Informed consent.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any identifiable cause of ischemic stroke other than PFO.&#xD;
&#xD;
          -  Isolated atrial septal defect or atrial septal defect associated with PFO with&#xD;
             significant left-to-right shunt requiring closure.&#xD;
&#xD;
          -  Previous surgical or endovascular treatments of PFO or ASA.&#xD;
&#xD;
          -  Known or suspected pregnancy (beta hCG test must be performed before inclusion).&#xD;
&#xD;
          -  Women who are breast-feeding.&#xD;
&#xD;
          -  Inability to comply with the treatments or follow-up requirements of the study.&#xD;
&#xD;
          -  No affiliation to the national health service.&#xD;
&#xD;
          -  Presence of other medical problems that would either lead to inability to complete the&#xD;
             trial or interfere with the assessment of outcomes.&#xD;
&#xD;
          -  Participation in another study.&#xD;
&#xD;
          -  Unable to understand the full meaning of the informed consent.&#xD;
&#xD;
          -  Related medical treatments of the trial:&#xD;
&#xD;
               -  Long-term oral anticoagulation or antiplatelet therapy is indicated for another&#xD;
                  disease.&#xD;
&#xD;
               -  Contra-indication to antiplatelet therapy or oral anticoagulants :&#xD;
&#xD;
                    -  3-arm trial : contra-indication to aspirin or clopidogrel or antivitamins K&#xD;
&#xD;
                    -  2-arm trial (closure vs antiplatelet therapy) : contra-indication to aspirin&#xD;
                       or clopidogrel&#xD;
&#xD;
                    -  2-arm trial (antivitamins K vs antiplatelet therapy : contra-indication to&#xD;
                       antivitamins K or to any antiplatelet drug&#xD;
&#xD;
               -  Increased risk of bleeding, such as severe hepatic insufficiency, current peptic&#xD;
                  ulceration, proliferative diabetic retinopathy, history of severe systemic&#xD;
                  bleeding (e.g. gastrointestinal bleeding, gross hematuria, intraocular bleeding,&#xD;
                  hemorrhagic stroke, or intracranial hemorrhage), or other history of bleeding&#xD;
                  diathesis or coagulopathy.&#xD;
&#xD;
          -  Related to endovascular treatments :&#xD;
&#xD;
               -  Infection requiring antibiotics (inclusion is possible after healing, 4 weeks&#xD;
                  after withdrawal of antibiotics).&#xD;
&#xD;
               -  Very large or multi-perforated ASA for which endovascular treatments is deemed&#xD;
                  too risky.&#xD;
&#xD;
               -  Presence of thrombus or occlusion between the venous access and the right atrium.&#xD;
&#xD;
               -  Presence of an inferior vena cava filter.&#xD;
&#xD;
               -  Severe pulmonary hypertension.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MAS Jean-Louis, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre hospitalier sainte Anne</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital Saint-Anne</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Mas JL, Derumeaux G, Guillon B, Massardier E, Hosseini H, Mechtouff L, Arquizan C, Béjot Y, Vuillier F, Detante O, Guidoux C, Canaple S, Vaduva C, Dequatre-Ponchelle N, Sibon I, Garnier P, Ferrier A, Timsit S, Robinet-Borgomano E, Sablot D, Lacour JC, Zuber M, Favrole P, Pinel JF, Apoil M, Reiner P, Lefebvre C, Guérin P, Piot C, Rossi R, Dubois-Randé JL, Eicher JC, Meneveau N, Lusson JR, Bertrand B, Schleich JM, Godart F, Thambo JB, Leborgne L, Michel P, Pierard L, Turc G, Barthelet M, Charles-Nelson A, Weimar C, Moulin T, Juliard JM, Chatellier G; CLOSE Investigators. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke. N Engl J Med. 2017 Sep 14;377(11):1011-1021. doi: 10.1056/NEJMoa1705915.</citation>
    <PMID>28902593</PMID>
  </results_reference>
  <verification_date>January 2017</verification_date>
  <study_first_submitted>November 21, 2007</study_first_submitted>
  <study_first_submitted_qc>November 21, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 22, 2007</study_first_posted>
  <last_update_submitted>October 18, 2017</last_update_submitted>
  <last_update_submitted_qc>October 18, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Patent Foramen Ovale</keyword>
  <keyword>Atrial septal aneurysm</keyword>
  <keyword>Antiplatelet therapy</keyword>
  <keyword>Oral anticoagulants</keyword>
  <keyword>Transcatheter closure</keyword>
  <keyword>Migraine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Ischemic Stroke</mesh_term>
    <mesh_term>Aneurysm</mesh_term>
    <mesh_term>Foramen Ovale, Patent</mesh_term>
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Dipyridamole</mesh_term>
    <mesh_term>Rivaroxaban</mesh_term>
    <mesh_term>Apixaban</mesh_term>
    <mesh_term>Dabigatran</mesh_term>
    <mesh_term>Antivitamins K</mesh_term>
    <mesh_term>Clopidogrel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

